Cure My Disease

Don't miss your cure!

 Log in / Sign up

Small study aims to unlock secrets of rare lung disease

NCT ID NCT00098072

Completed Knowledge-focused Sponsor: National Institutes of Health Clinical Center (CC) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 01, 2026 · Updated 4 times

Summary

This completed Phase 1 study looked at 27 people with and without pulmonary hypertension to learn more about how blood vessel problems contribute to the disease. Researchers used heart catheterization, imaging, and blood tests to find biomarkers and understand disease mechanisms. The goal was to improve detection and treatment, not to test a new drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to

If successful, this research could point toward better ways to detect and treat pulmonary hypertension, and possibly slow its progression.

What could go wrong

This is an early, small study focused on understanding the disease, not testing a new treatment. It may not lead directly to new therapies.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SICKLE CELL DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

drug- or toxin-induced pulmonary arterial hypertension Eisenmenger syndrome HIV infectious disease hypertensive disorder idiopathic pulmonary arterial hypertension portal hypertension pulmonary arterial hypertension pulmonary hypertension owing to lung disease and/or hypoxia rheumatic disorder sickle cell disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SECONDARY PULMONARY ARTERIAL HYPERTENSION

Contacts and locations

Locations

  • National Institutes of Health Clinical Center

    Bethesda, Maryland, 20892, United States